Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Arrowhead Research Surges as It Advances Its Drug for Hepatitis B into Phase 2

By Todd Campbell - Mar 7, 2014 at 2:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Arrowhead is leveraging RNAi technology acquired from Roche in 2011 to develop a new therapy for hepatitis B.

Shares in speculative biotechnology company Arrowhead ( ARWR -3.14% ), which was one of 2013's best performing biotechs, jumped nearly 25% following news its lead compound is heading into phase 2 trials.

The company won approval from Hong Kong regulators to start a phase 2a trial for its ARC-520 drug for hepatitis B. ARC-520 will be dosed alongside Bristol-Myers' Hepatitis B drug Baraclude, a therapy that generates more than a billion in annual sales for Bristol. 

ARWR Chart

ARWR data by YCharts

Coming of age
The study will help Arrowhead determine efficacy and dosing, important considerations for moving the drug into much larger trials. The launch of the phase 2 trial comes following phase 1 results showing ARC-520 was generally safe and well-tolerated in six different doses.

While investors may not be familiar with Arrowhead, the company isn't a new player in RNAi. In fact, it acquired its dynamic polyconjugates technology from Roche when it bought Roche's RNAi assets in a 2011 fire sale.

Roche had previously invested big money into RNAi research in hopes such targeted therapies would usher in a new generation of disease busting drugs.  

Unfortunately, advances in RNAi didn't come quickly enough for Roche, prompting its exit. Merck soon followed Roche's lead, shuttering its own RNAi program in 2011. Merck finally sold those RNAi assets to Alnylam ( ALNY -6.28% ) earlier this year.

Now, Roche likely wishes it had held on given excitement surrounding RNAi is returning thanks to therapies from Isis, Alnylam, and now Arrowhead, advancing through clinic.

Isis, through its partners, has 20 compounds in phase 2 or phase 3, and Alnylam's most advanced compound, patisiran for TTR-Mediated Amyloidosis, is in phase 3.  Additionally, Isis already has one FDA approved drug, Kynamro, being sold by Sanofi's Genzyme unit.

Big opportunity
Thanks to vaccinations, the number of people with acute hepatitis B has fallen 82% in the U.S. since 1990. Despite the drop-off, the number of chronic cases requiring treatment remains high. An estimated 800,000 to 1.4 million people are diagnosed in the U.S., and 240 million are diagnosed worldwide. That sheer size translates into more than 600,000 deaths annually from the disease.

Hepatitis B is most common where vaccines have been slow to penetrate; including sub saharan Africa and East Asia, where between 5% and 10% of the population is infected.

As a result, international sales of hepatitis B treatments are higher overseas than in America and Western Europe. Currently, the bulk of that treatment comes in the form of side effect laden interferon, antivirals and Bristol's Baraclude. Baraclude's success hints at the potential for ARC-520. Sales of Baraclude totaled more than $400 million in the fourth quarter, and global sales of $1.5 billion were 10% higher last year than in 2012.

Unfortunately, all three of these current treatments aim at slowing disease progression, rather than curing it. That means those diagnosed with chronic hepatitis B remain at risk for liver cancer and liver failure, both of which offer a poor prognosis.

Fool-worthy final thoughts
Excitement surrounding Arrowhead's ARC-520 may prove justified given the backdrop of a huge global unmet need for new treatment options, and potential pricing power based on hefty price tags for next generation hepatitis C drugs including Gilead's Sovaldi.

However, ARC-520 could still be years away from being commercialized, so investors should approach Arrowhead with caution. Fools will want to stay tuned in to see early results from this phase 2 trial, which should come in the third quarter.  

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Arrowhead Pharmaceuticals, Inc. Stock Quote
Arrowhead Pharmaceuticals, Inc.
ARWR
$67.50 (-3.14%) $-2.19
Alnylam Pharmaceuticals, Inc. Stock Quote
Alnylam Pharmaceuticals, Inc.
ALNY
$171.36 (-6.28%) $-11.49

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/04/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.